Sinco Pharmaceuticals Holdings Limited

Informe acción SEHK:6833

Capitalización de mercado: HK$469.6m

Sinco Pharmaceuticals Holdings Dirección

Dirección controles de criterios 3/4

El CEO de Sinco Pharmaceuticals Holdings' es Min Jin , nombrado en Mar 2023, tiene una permanencia de 1.08 años. compensación anual total es CN¥1.66M, compuesta por 94% salario y 6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.67% de las acciones de la empresa, por valor de HK$3.35M. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 5.4 años, respectivamente.

Información clave

Min Jin

Chief Executive Officer (CEO)

CN¥2.0m

Compensación total

Porcentaje del salario del CEO94.6%
Permanencia del CEO1.2yrs
Participación del CEO0.7%
Permanencia media de la dirección1.3yrs
Promedio de permanencia en la Junta Directiva5.5yrs

Actualizaciones recientes de la dirección

Recent updates

Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings

Apr 02
Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings

Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks

Mar 08
Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

Nov 07
Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Jun 26
A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

May 30
Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet

Oct 26
Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today

Feb 04
Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today

I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease

Oct 25
I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease

Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings

Jun 10
Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings

Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt

May 24
Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock

Apr 20
Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock

We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings

Feb 16
We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings

How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 11
How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?

Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?

Dec 07
Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Min Jin en comparación con los beneficios de Sinco Pharmaceuticals Holdings?
FechaCompensación totalSalarioIngresos de la empresa
Dec 31 2023CN¥2mCN¥2m

CN¥42m

Sep 30 2023n/an/a

CN¥35m

Jun 30 2023n/an/a

CN¥27m

Mar 31 2023n/an/a

CN¥48m

Dec 31 2022CN¥2mCN¥2m

CN¥69m

Compensación vs. Mercado: La compensación total ($USD229.04K) de Min está en línea con el promedio de empresas de tamaño similar en el mercado Hong Kong ($USD234.25K).

Compensación vs. Ingresos: La compensación de Min ha sido consistente con los resultados de la empresa en el último año.


CEO

Min Jin (45 yo)

1.2yrs

Permanencia

CN¥1,959,000

Compensación

Mr. Min Jin was Co-Chief Executive Officer at Sinco Pharmaceuticals Holdings Limited since November 2020 until March 29, 2023. He has experience in the pharmaceutical industry. He served as Director of mar...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Xiangbin Huang
Executive Chairman13.1yrsCN¥7.10m51.65%
CN¥ 242.5m
Min Jin
Chief Executive Officer1.2yrsCN¥1.96m0.67%
CN¥ 3.2m
Shifeng Lei
Executive Directorno dataCN¥1.09msin datos
Yifan Li
Chief Financial Officer8.9yrssin datossin datos
Zhijian Huang
Executive Directorless than a yearsin datossin datos
Yunlu Peng
Company Secretary4.6yrssin datossin datos
Tao Zhang
President of Sichuan Sinco Pharmaceuticals Co. Ltd.1.5yrssin datossin datos

1.3yrs

Permanencia media

43yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 6833 no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Xiangbin Huang
Executive Chairman13.1yrsCN¥7.10m51.65%
CN¥ 242.5m
Shifeng Lei
Executive Director1.2yrsCN¥1.09msin datos
Zhijian Huang
Executive Directorless than a yearsin datossin datos
Ying Kit Lau
Independent Non-Executive Director5.5yrsCN¥300.00ksin datos
Wenfang Liu
Independent Non-Executive Director8.3yrsCN¥300.00ksin datos
Qing Wang
Independent Non-Executive Director8.3yrsCN¥300.00ksin datos
Zhizhong Bai
Independent Non-Executive Director3.7yrsCN¥300.00ksin datos

5.5yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de 6833 se considera experimentada (5.4 años de antigüedad promedio).